Speaker Profile
Ph.D., CEO, NysnoBio
Biography
Jennifer is the creative force behind NysnoBio, responsible for the business and scientific focus of the company as CEO. She has over 20 years of experience in the biopharmaceutical industry, including 13 years in neurodegenerative diseases at Elan Pharmaceuticals.As VP, Head of Discovery Research at Elan, Jennifer delivered multiple novel molecules for Parkinsons disease from initial discovery to candidate selection.In 2019, Jennifer founded NysnoBio to focus on gene therapy approaches. She has more than ten patents and over 40 publications. She has served as a reviewer for multiple scientific journals, and on the SAB of the Michael J. Fox Foundation for over 18 years.Outside the office, Jennifer has been a member of the USA Track Field 100Km Team, earning bronze and silver medals in the national championships, as well as holding the record for the most wins in the Angeles Crest 100-mile trail race.
Talk
Parkin Gene Therapy for Parkinson's Disease
NysnoBio is advancing a novel gene therapy to restore mitochondrial function in Parkinson's Disease (PD). Loss of the Parkin gene is a genetic cause of PD, and Parkin's role to restore damaged mitochondria demonstrates a unique opportunity to treat genetic and sporadic populations of the second most common neurodegenerative disorder by replacing the Parkin gene.
Emerging Therapeutics Showcase:
NysnoBio
NysnoBio is advancing genetic therapies to treat rare and common neurodegenerative disorders. Our platform is aimed at addressing disease at the root cause with restorative therapies having broad application for therapeutic benefit.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
